HGH 191AA (Somatropin) (10iu–36iu)

Human Growth Hormone (HGH, Somatropin, rHGH, 191 Amino Acid Sequence, 10IU / 15IU): Recombinant Human Growth Hormone Produced by E. coli or Mammalian Cell Expression Systems — Identical to the Endogenous 191-Amino-Acid Single-Chain Polypeptide Hormone Secreted by the Anterior Pituitary Somatotrophs, with a Molecular Weight of ~22.1 kDa, That Regulates Postnatal Growth, Metabolism, Body Composition, Bone Density, Muscle Mass, Fat Metabolism, Tissue Repair, and Aging — Available in Both 10IU and 15IU Vial Formats for Investigational Research in Growth Hormone Axis, Body Composition, Anti-Aging, Recovery, and Metabolic Health

Human growth hormone (HGH, also known as somatotropin, somatropin [recombinant human growth hormone, rHGH], or growth hormone [GH]) is a single-chain polypeptide hormone consisting of 191 amino acids with a molecular weight of approximately 22.1 kDa (22,125 Daltons), produced primarily by the somatotroph cells of the anterior pituitary gland (which constitute approximately 30-40% of anterior pituitary cells and are the most abundant cell type in the pituitary). The 191-amino-acid sequence of mature human GH was first determined by Li and colleagues in 1966 (building on earlier work by Li and Papkoff who first purified GH in 1956), and the gene encoding human GH (GH1, located on chromosome 17q23.3) was cloned and sequenced in 1979, paving the way for recombinant production. HGH has a distinctive three-dimensional structure consisting of four anti-parallel alpha-helices (helices 1-4, connected by loops) arranged in an "up-up-down-down" topology, with two disulfide bonds (Cys53-Cys165 and Cys182-Cys189) that stabilize the structure — the C-terminal disulfide bond forms a small loop at the carboxyl terminus that is important for receptor binding. HGH is a member of the somatotropin/prolactin family of hormones, which also includes prolactin (PRL), human placental lactogen (hPL), and growth hormone variant (GH-V, produced by the placenta during pregnancy). The biological effects of HGH are mediated through binding to the growth hormone receptor (GHR) — a transmembrane protein of the class I cytokine receptor superfamily, expressed on virtually every cell type in the body but particularly abundant on hepatocytes (liver cells), adipocytes (fat cells), myocytes (muscle cells), chondrocytes (cartilage cells, particularly in the epiphyseal growth plates of long bones), osteoblasts/osteoclasts (bone cells), fibroblasts, immune cells, and neurons. A unique and critical feature of GHR activation is that HGH binding induces GHR dimerization — one HGH molecule binds to two GHR molecules simultaneously (binding site 1 on HGH interacts with one GHR with high affinity, and binding site 2 interacts with a second GHR with lower affinity), bringing the intracellular domains of the two GHR molecules into close proximity, which activates the associated Janus kinase 2 (JAK2) tyrosine kinase. Activated JAK2 phosphorylates multiple downstream targets, initiating several signaling cascades: (1) JAK2-STAT5 pathway (the primary signaling pathway for most GH effects) — JAK2 phosphorylates signal transducer and activator of transcription 5 (STAT5, particularly STAT5b), which dimerizes, translocates to the nucleus, and binds to specific DNA sequences (gamma-interferon activated sequences, GAS) to regulate gene transcription — including the gene encoding insulin-like growth factor 1 (IGF-1, also known as somatomedin C), which is produced primarily in the liver in response to GH and mediates many of GH's growth-promoting and metabolic effects; (2) JAK2-MAPK/ERK pathway — JAK2 activates the mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) cascade, which is involved in cell proliferation, differentiation, and survival; (3) JAK2-PI3K/Akt pathway — JAK2 activates phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt), which is involved in glucose uptake, cell survival, protein synthesis (via mTOR), and anti-apoptotic effects; (4) JAK2-SHC/Grb2 pathway — involved in additional MAPK activation and cellular responses. GHR signaling is tightly regulated by several negative feedback mechanisms including: suppressor of cytokine signaling (SOCS) proteins (particularly SOCS1, SOCS2, and SOCS3, which are induced by GH and inhibit JAK2 activity), protein tyrosine phosphatases (PTPs, such as PTP1B and SHP-2, which dephosphorylate JAK2 and GHR), and GHR internalization and degradation (via ubiquitination and proteasomal/lysosomal degradation). The physiological effects of HGH are extraordinarily diverse and affect virtually every organ system, but they can be broadly categorized into: (1) Growth-promoting effects (anabolic, trophic) — HGH stimulates postnatal linear growth (particularly through IGF-1-mediated proliferation of chondrocytes in the epiphyseal growth plates of long bones, which is why GH deficiency in childhood causes dwarfism and GH excess causes gigantism before growth plate closure, or acromegaly after closure); stimulates organ growth (liver, kidneys, heart, intestines, etc.); stimulates muscle growth (increased protein synthesis, decreased protein breakdown, increased lean body mass); stimulates bone growth and remodeling (increased bone mineral density, through effects on osteoblasts and osteoclasts); stimulates tissue repair and regeneration (wound healing, tissue recovery after injury); (2) Metabolic effects — HGH has complex and sometimes opposing effects on metabolism: (a) Lipolytic effects — HGH stimulates breakdown of adipose tissue (fat), increasing circulating free fatty acids (FFAs) and glycerol, and reducing fat mass (particularly visceral fat); this is mediated through activation of hormone-sensitive lipase (HSL) in adipocytes and increased β-adrenergic sensitivity; (b) Protein anabolic effects — HGH stimulates protein synthesis and inhibits protein breakdown in muscle and other tissues, leading to positive nitrogen balance and increased lean body mass; (c) Carbohydrate metabolic effects — HGH is a counter-regulatory hormone that increases insulin resistance (reducing glucose uptake in muscle and adipose tissue, increasing hepatic gluconeogenesis), which can lead to hyperglycemia and increased insulin secretion at high doses — this is why GH excess (acromegaly) is associated with diabetes mellitus, and why GH therapy requires monitoring of glucose metabolism, particularly in diabetic or prediabetic individuals; (d) Mineral and electrolyte effects — HGH causes sodium and water retention (through increased renal sodium reabsorption and IGF-1-mediated effects), which can lead to edema, particularly at the initiation of therapy or at higher doses; (3) Cardiovascular effects — HGH has important effects on the cardiovascular system: it can improve cardiac function (increased cardiac output, improved left ventricular ejection fraction) in GH-deficient patients and in some heart failure models; it affects lipid metabolism (reducing LDL cholesterol and triglycerides, increasing HDL cholesterol in some studies); it can affect vascular function (improving endothelial function, increasing nitric oxide production through IGF-1); however, GH excess (acromegaly) is associated with increased cardiovascular mortality (cardiomyopathy, hypertension, arrhythmias), indicating that the cardiovascular effects are dose- and context-dependent; (4) Immune system effects — HGH and IGF-1 have immunomodulatory effects, stimulating thymic function (thymus is the site of T-cell maturation, and GH can promote thymopoiesis, particularly important in aging where thymic involution occurs), increasing lymphocyte proliferation and function, enhancing natural killer (NK) cell activity, and modulating cytokine production; (5) Central nervous system effects — GHR is expressed in the brain, and HGH/IGF-1 have effects on cognitive function, memory, mood, sleep (GH is secreted primarily during slow-wave sleep, and GH secretion patterns are linked to sleep architecture), neuroprotection, and neurogenesis (particularly in the hippocampus); GH deficiency is associated with impaired quality of life, fatigue, depression, and cognitive difficulties, which can improve with GH replacement; (6) Aging-related effects — HGH secretion declines progressively with age (somatopause — GH secretion decreases by approximately 14% per decade after age 20-30, with a 50% reduction by age 60 and 70-80% reduction by age 80), and this decline has been linked to many features of aging including decreased lean muscle mass, increased fat mass (particularly visceral fat), decreased bone density, decreased skin thickness and elasticity, decreased energy, impaired recovery, and reduced quality of life — this has led to interest in GH as a potential "anti-aging" therapy, although the evidence for this is mixed and the risks (particularly glucose intolerance, edema, carpal tunnel syndrome, and potential cancer risk) must be carefully considered. HGH is secreted in a pulsatile fashion, with the majority of daily GH secretion occurring during the first few hours of deep (slow-wave) sleep, with additional smaller pulses during the day (particularly after meals, exercise, and stress). GH secretion is regulated by two hypothalamic hormones with opposing effects: (a) Growth hormone-releasing hormone (GHRH, somatocrinin) — stimulates GH synthesis and release from somatotrophs (via Gs-coupled GHRHR → cAMP → PKA); (b) Somatostatin (SST, growth hormone-inhibiting hormone, GHIH) — inhibits GH release (via Gi-coupled SSTRs → reduced cAMP, reduced calcium influx); the pulsatile pattern of GH secretion results from the reciprocal interaction of GHRH (stimulating pulses) and somatostatin (inhibiting between pulses), with additional modulation by ghrelin (the "hunger hormone," which stimulates GH release through GHSR-1a), IGF-1 negative feedback (IGF-1 inhibits GH release at both the pituitary and hypothalamic levels, and stimulates somatostatin release), and various other factors including exercise, stress, sleep, nutrition (amino acids, particularly arginine and lysine, can stimulate GH release), hypoglycemia, and hormones (testosterone, estrogen, thyroid hormone all modulate GH secretion). Recombinant human growth hormone (rHGH, somatropin) was first produced in 1979 using E. coli expression systems, and the first recombinant HGH product (Protropin, Genentech) was approved by the FDA in 1985 — prior to this, the only source of HGH was human cadaver pituitaries (extracted from autopsy specimens), which was used from the 1950s to 1985 but was discontinued due to the risk of transmitting Creutzfeldt-Jakob disease (CJD, a prion disease — several patients who received cadaver GH developed CJD years later, leading to the withdrawal of cadaver-derived GH worldwide). Modern recombinant HGH is produced using various expression systems including E. coli (bacterial), Chinese hamster ovary (CHO) cells (mammalian), mouse C127 cells, and others, with rigorous purification and quality control to ensure the product is identical to endogenous human GH (191 amino acids, correct folding, correct disulfide bonds, no extraneous amino acids or modifications). It is important to note that some early recombinant HGH products (such as Protropin/methionyl HGH, met-HGH) had an additional methionine at the N-terminus (192 amino acids), which was needed for bacterial expression but could cause antibody formation; modern somatropin products are the exact 191-amino-acid sequence identical to endogenous HGH. HGH is measured and dosed in International Units (IU) or milligrams (mg), with the conversion factor being approximately 1 mg = 3 IU (based on the WHO international standard for somatropin, where 1 mg = 3.0 IU — although the exact conversion may vary slightly by product and batch). The 10IU and 15IU vial formats (approximately 3.33mg and 5mg respectively, at 1mg = 3IU) provide convenient, pre-measured doses suitable for a range of investigational applications: typical research doses range from 2-8 IU per day (subcutaneous, often administered in the evening to mimic natural nocturnal GH secretion, or split into 2-3 daily doses to reduce peak-related side effects), with a 10IU vial providing 1-5 days of therapy at 2-10 IU/day, and a 15IU vial providing 2-7.5 days at 2-7.5 IU/day; for diagnostic GH stimulation testing, lower doses may be used; for anti-aging or wellness research, lower doses (1-3 IU/day) are often used, while for bodybuilding or performance enhancement (controversial and banned by WADA), higher doses (4-10+ IU/day, often in combination with other peptides or hormones) may be used. Reconstitution: add 1-3 mL of bacteriostatic water (or sterile water for IM/IV use — bacteriostatic water is preferred for multi-dose vials as it contains 0.9% benzyl alcohol which prevents bacterial growth, allowing the reconstituted vial to be used for multiple doses over several days) to yield 10-3.33 IU/mL for the 10IU vial, or 15-5 IU/mL for the 15IU vial; for example, adding 1 mL to a 10IU vial yields 10 IU/mL, so a 2 IU dose = 0.2 mL, 4 IU = 0.4 mL, 5 IU = 0.5 mL, 10 IU = 1.0 mL; adding 1.5 mL to a 15IU vial yields 10 IU/mL, so 2 IU = 0.2 mL, 5 IU = 0.5 mL, 10 IU = 1.0 mL, 15 IU = 1.5 mL. When reconstituting, the bacteriostatic water should be added slowly down the side of the vial (not directly onto the lyophilized powder, which can cause denaturation and foaming), and the vial should be gently swirled (not shaken vigorously) to dissolve — HGH is a protein and vigorous shaking can cause denaturation (loss of biological activity) and foaming. Reconstituted HGH is stable for 14-30 days when refrigerated at 2-8°C (with bacteriostatic water; sterile water without bacteriostatic agent should be used within 24-48 hours due to risk of bacterial contamination), protected from light; do NOT freeze reconstituted HGH (freezing can denature the protein); the lyophilized powder is stable for 24-36 months from manufacture when stored at 2-8°C (refrigerator, NOT freezer — freezing can denature the protein), protected from light and moisture. The safety profile of HGH is well-characterized from decades of clinical use in GH-deficient patients, and when used at physiological replacement doses, HGH is generally well-tolerated with a favorable safety profile. However, at supraphysiological doses (as used in some bodybuilding, anti-aging, or performance enhancement contexts), the risk of side effects increases significantly. Common side effects of HGH therapy include: (1) Fluid retention/edema — HGH causes sodium and water retention, particularly at the initiation of therapy or at higher doses, leading to peripheral edema (swelling of hands, feet, ankles), facial puffiness, and weight gain (due to water retention, not fat gain); this is usually mild and resolves with dose reduction or continued therapy; (2) Carpal tunnel syndrome / paresthesia — fluid retention and tissue swelling can compress the median nerve at the wrist, causing carpal tunnel syndrome (numbness, tingling, pain, weakness in the hands and fingers, particularly at night); this is more common at higher doses and in individuals with pre-existing carpal tunnel issues; dose reduction usually resolves symptoms; (3) Arthralgia/myalgia — joint pain and muscle aches, particularly at the initiation of therapy, due to tissue growth and fluid retention; usually mild and transient; (4) Headache — particularly at the initiation of therapy, possibly due to fluid retention and changes in intracranial pressure; usually mild and transient; (5) Glucose intolerance/hyperglycemia — HGH is a counter-regulatory hormone that increases insulin resistance, which can lead to elevated blood glucose levels, increased insulin secretion, and in some cases, frank diabetes mellitus (particularly in individuals with pre-existing insulin resistance, prediabetes, or diabetes); glucose monitoring is recommended, particularly in diabetic or prediabetic individuals, and insulin/oral hypoglycemic doses may need adjustment; (6) Lipid changes — HGH generally has favorable effects on lipids (reducing LDL and triglycerides, increasing HDL in some studies), but individual responses may vary; (7) Increased liver enzymes — mild, transient elevations in liver transaminases (ALT, AST) may occur, particularly at higher doses; usually resolve with dose reduction or continued therapy; (8) Gynecomastia — in men, HGH can cause gynecomastia (breast tissue enlargement) at higher doses, possibly due to increased aromatization of testosterone to estrogen (HGH can increase testosterone levels in some contexts, and IGF-1 may affect sex hormone metabolism); this is usually mild and resolves with dose reduction; (9) Skin changes — increased skin thickness, oiliness, acne (particularly in individuals prone to acne), and increased sweating (particularly at night, due to increased metabolic rate); (10) Hypothyroidism — HGH can increase the conversion of T4 to T3 (the active thyroid hormone), which can unmask central hypothyroidism or worsen existing hypothyroidism; thyroid function monitoring is recommended, particularly in individuals with known thyroid disease. Rare but serious side effects include: (1) Intracranial hypertension (pseudotumor cerebri) — increased intracranial pressure causing headache, visual changes, papilledema; rare but requires medical attention; (2) Pancreatitis — inflammation of the pancreas, causing severe abdominal pain; rare but has been reported; (3) Slipped capital femoral epiphysis (SCFE) — in children with open growth plates, rapid growth can cause slippage of the femoral head; rare but requires orthopedic evaluation; (4) Progression of scoliosis — in children with scoliosis, rapid growth can worsen spinal curvature; (5) Allergic reactions — rare, but possible (particularly with early met-HGH products; modern 191aa somatropin has very low immunogenicity); (6) Cancer risk — this is a controversial and heavily debated topic. HGH and IGF-1 are mitogenic (cell growth-promoting) and anti-apoptotic (inhibiting programmed cell death), and there is theoretical concern that GH/IGF-1 could promote the growth of existing cancers or increase cancer risk. Epidemiological studies have produced mixed results: some studies have found associations between higher IGF-1 levels and increased risk of certain cancers (particularly prostate, breast, colorectal), while other studies have not found significant associations. In GH-deficient patients receiving physiological replacement doses, most studies have not found a significant increase in cancer risk, although long-term surveillance is recommended. However, at supraphysiological doses (as used in bodybuilding/performance enhancement), the theoretical cancer risk may be increased, and individuals with active malignancy or a history of certain cancers should generally avoid GH therapy. The FDA requires a warning on HGH products regarding potential risk of neoplasia; (7) Cardiovascular effects — while physiological GH replacement can improve cardiovascular risk factors (lipids, body composition, endothelial function), GH excess (acromegaly) is associated with increased cardiovascular mortality (cardiomyopathy, hypertension, arrhythmias, heart failure), and supraphysiological GH doses may have adverse cardiovascular effects; (8) Worsening of sleep apnea — fluid retention and tissue growth can worsen obstructive sleep apnea, particularly in overweight/obese individuals; (9) Ear disorders — otitis media, hearing loss, particularly in children with Turner syndrome or Prader-Willi syndrome (specific patient populations). Contraindications to HGH therapy include: (1) active malignancy (active cancer — GH/IGF-1 can theoretically stimulate tumor growth); (2) proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy (GH can worsen retinal neovascularization); (3) acute critical illness (GH therapy in critically ill patients has been associated with increased mortality in some studies — particularly in the acute phase of illness); (4) hypersensitivity to HGH or any component of the formulation; (5) Prader-Willi syndrome with severe obesity or severe respiratory impairment (increased risk of sudden death in this specific population); (6) closed epiphyses in children being treated for growth failure (GH is not effective for increasing height after growth plates have closed); (7) pregnancy and breastfeeding (insufficient safety data — GH is generally not recommended during pregnancy/breastfeeding, although GH deficiency in pregnancy may be managed in specialized cases). WADA status: HGH is a banned substance by the World Anti-Doping Agency (WADA) and is prohibited both in-competition and out-of-competition for athletes, due to its performance-enhancing potential (increased muscle mass, reduced fat mass, improved recovery). WADA has implemented specific testing methods for HGH (including the "isoform test" which detects the ratio of pituitary GH to recombinant GH, and the "biomarker test" which measures IGF-1 and other GH-responsive markers), and several high-profile athletes have been sanctioned for HGH use. As of 2026, recombinant HGH (somatropin) is approved by the FDA and other regulatory agencies for several clinical indications including: pediatric growth hormone deficiency (GHD), adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease-related growth failure, short stature homeobox-containing (SHOX) gene deficiency, Noonan syndrome, small for gestational age (SGA) infants who fail to catch up by age 2-4, idiopathic short stature (ISS), and HIV/AIDS-related wasting/cachexia. However, the research-grade HGH supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

The Molecular Biology of HGH: 191-Amino-Acid Structure, GHR Dimerization, JAK2-STAT5 Signaling, and the IGF-1 Axis

To fully understand HGH's profound and diverse biological effects, it is essential to understand its molecular structure, the unique mechanism of growth hormone receptor (GHR) activation, the complex signaling cascades it initiates, and the central role of insulin-like growth factor 1 (IGF-1) as the primary mediator of many GH effects. The molecular structure of HGH is that of a single-chain, 191-amino-acid polypeptide with a molecular weight of 22,125 Daltons (~22.1 kDa). The mature HGH protein is derived from a 217-amino-acid preprohormone (pre-GH) that includes a 26-amino-acid signal peptide (which directs the protein to the secretory pathway and is cleaved off during secretion, leaving the mature 191-amino-acid hormone). The amino acid sequence of HGH was first fully determined by Li, Liu, and Dixon in 1966 (building on Li and Papkoff's 1956 purification of GH from human pituitaries), and the GH1 gene (located on chromosome 17q23.3, within a cluster of five related genes including GH1 [pituitary GH], GH2 [placental GH variant, GH-V], CSH1 [human placental lactogen, hPL], CSH2 [hPL variant], and CSHL1 [CSH-like gene]) was cloned and sequenced in 1979 by several groups simultaneously, paving the way for recombinant production. The three-dimensional structure of HGH, determined by X-ray crystallography (first by Abdel-Meguid et al. in 1987), reveals a distinctive four-helix bundle topology consisting of four anti-parallel alpha-helices (helix 1: residues 1-34, helix 2: residues 56-86, helix 3: residues 91-128, helix 4: residues 155-189) arranged in an "up-up-down-down" orientation (helices 1 and 2 point up, helices 3 and 4 point down, with the helices connected by three loops: loop 1 [residues 35-55, connecting helices 1 and 2], loop 2 [residues 87-90, connecting helices 2 and 3], loop 3 [residues 129-154, connecting helices 3 and 4]). The structure is stabilized by two disulfide bonds: (1) Cys53-Cys165 (a large loop connecting helix 1/loop 1 region to helix 4, stabilizing the overall four-helix bundle); (2) Cys182-Cys189 (a small C-terminal loop near the carboxyl terminus, which is important for receptor binding — this C-terminal disulfide loop is a conserved feature of the somatotropin/prolactin family). HGH has two distinct receptor-binding sites on its surface: (a) Binding site 1 — a high-affinity binding site formed by residues on helices 1, 4, and loop 3 (including key residues such as Arg16, His18, Gln22, Phe25, Asp26, Gln29, Leu32, Arg64, Asn109, Asp116, Leu117, Glu119, Gly120, Thr123, Gly131, Arg134, Phe139, Asp171, Phe176, Arg178, Cys182, Gly185, Cys189) — this site binds to one GHR molecule with high affinity (Kd ~0.1-1 nM); (b) Binding site 2 — a lower-affinity binding site formed by residues on helices 1 and 3 (including key residues such as Asp11, Gly12, Lys15, Leu19, Asn23, Pro28, Lys41, Tyr43, Gln46, Leu49, Pro59, Ser62, Asn63, Leu66, Arg77, Leu80, Ser84, Phe85, Gln91, Leu94, Lys97, Tyr103, Asp107, Asn109, Leu110, Pro113, Thr114, Gly115, Asp116, Leu117, Ser118, Glu119, Gly120, Thr123, Ile127, Gln129, Glu130, Gly131, Thr133, Arg134, Phe139, Glu146, Thr148, Gly151, Ser154, Tyr155, Ser156, Asn158, Val159, Leu160, Arg161, Leu162, His163, Gln164, Cys165, Phe166, Asp167, Ser168, Leu169, Leu170, Asp171, Leu172, Arg173, Ile174, Val175, Phe176, Leu177, Arg178, Ser179, Val180, Cys182, Gly183, Pro184, Gly185, Cys186, Phe187, Lys188, Cys189, Gly190, Lys191) — this site binds to a second GHR molecule with lower affinity (Kd ~1-10 μM), and it is the sequential binding of site 1 to one GHR followed by site 2 to a second GHR that induces GHR dimerization (the "sequential dimerization" model). The growth hormone receptor (GHR) is a transmembrane protein of the class I cytokine receptor superfamily (which also includes receptors for prolactin, erythropoietin, thrombopoietin, interleukins 2-7, granulocyte colony-stimulating factor, and others), encoded by the GHR gene on chromosome 5p13.1-p12. GHR consists of: (1) an extracellular domain (ECD, ~246 amino acids) — composed of two fibronectin type III-like subdomains (subdomain 1 [N-terminal, cytokine receptor homology domain] and subdomain 2 [membrane-proximal]), with the HGH binding site located primarily in subdomain 1; the ECD contains several N-linked glycosylation sites (which are important for receptor folding, trafficking, and function), and a conserved WSXWS motif (Trp-Ser-X-Trp-Ser, where X is any amino acid) in the membrane-proximal subdomain — a hallmark of class I cytokine receptors; (2) a single transmembrane domain (~24 amino acids, hydrophobic alpha-helix that spans the cell membrane); (3) an intracellular domain (ICD, ~350 amino acids) — which does NOT have intrinsic kinase activity (unlike receptor tyrosine kinases), but instead constitutively associates with Janus kinase 2 (JAK2, a non-receptor tyrosine kinase of ~130 kDa) through a conserved proline-rich motif (the "box 1" motif, Pro-Pro-X-Pro-X-Pro, located in the membrane-proximal region of the ICD); the ICD also contains multiple tyrosine residues that become phosphorylated by JAK2 upon receptor activation, serving as docking sites for downstream signaling molecules (including STAT5, SHC, Grb2, IRS-1, and others); the ICD contains "box 2" motif (another conserved region involved in signaling), and several serine/threonine residues that are involved in receptor internalization and degradation. A critical and unique feature of GHR activation is the obligate GHR dimerization induced by HGH binding. Unlike many receptors that exist as pre-formed dimers, GHR is thought to exist primarily as a monomer (or possibly an inactive dimer) in the absence of ligand, and HGH binding induces active dimerization through the sequential binding mechanism described above: first, HGH binding site 1 binds to one GHR molecule (high affinity), then HGH binding site 2 binds to a second GHR molecule (lower affinity), bringing the two GHR molecules into close proximity and proper orientation (the two GHR molecules are arranged asymmetrically, with the two intracellular domains brought into close apposition). This dimerization brings the JAK2 molecules associated with each GHR's ICD into close proximity, allowing them to trans-phosphorylate each other (one JAK2 phosphorylates the other, and vice versa), activating JAK2's kinase activity. Activated JAK2 then phosphorylates multiple tyrosine residues on the GHR ICD, creating docking sites for downstream signaling molecules that contain SH2 (Src homology 2) or PTB (phosphotyrosine binding) domains. The JAK2-STAT5 signaling pathway is the primary and best-characterized pathway mediating most of HGH's biological effects: (1) Activated JAK2 phosphorylates STAT5 (signal transducer and activator of transcription 5, particularly STAT5b — the STAT5 isoform primarily responsible for GH signaling; STAT5a is more involved in prolactin signaling, although both can be activated by GH) on specific tyrosine residues (Tyr694 in STAT5a, Tyr699 in STAT5b); (2) Phosphorylated STAT5 molecules dimerize (through reciprocal SH2 domain-phosphotyrosine interactions); (3) The STAT5 dimer translocates to the nucleus (through importin-mediated nuclear import); (4) In the nucleus, the STAT5 dimer binds to specific DNA sequences called GAS elements (gamma-interferon activated sequences, consensus sequence TTCNNNGAA, where N is any nucleotide) in the promoter/enhancer regions of GH-responsive genes; (5) STAT5 binding recruits transcriptional co-activators (including CBP/p300, which have histone acetyltransferase activity, and others) and the basal transcription machinery, leading to increased (or in some cases, decreased) transcription of target genes. The most important GH/STAT5 target gene is IGF-1 (insulin-like growth factor 1, also known as somatomedin C) — STAT5 binds to multiple GAS elements in the IGF-1 gene promoter and enhancer regions, strongly stimulating IGF-1 transcription, particularly in hepatocytes (liver cells), which are the primary source of circulating IGF-1 (accounting for ~75-80% of circulating IGF-1; the remaining 20-25% is produced locally in various tissues including muscle, bone, cartilage, adipose, kidney, and others, where it acts in an autocrine/paracrine manner). IGF-1 is a 70-amino-acid peptide (~7.6 kDa) with structural homology to proinsulin (it consists of B chain, C peptide, and A chain, similar to insulin, but the C peptide is not cleaved in mature IGF-1, so it is a single-chain peptide), and it mediates many of HGH's growth-promoting and metabolic effects: (a) Growth-promoting effects — IGF-1 stimulates proliferation of chondrocytes in the epiphyseal growth plates of long bones (the primary mechanism of GH-mediated linear growth in children), stimulates osteoblast proliferation and bone formation, stimulates muscle cell proliferation and protein synthesis, stimulates organ growth, and stimulates tissue repair/regeneration; (b) Metabolic effects — IGF-1 has insulin-like effects (increasing glucose uptake in muscle and adipose tissue, inhibiting hepatic gluconeogenesis — these effects oppose GH's counter-regulatory effects, creating a complex metabolic balance), stimulates protein synthesis, inhibits protein breakdown, and has complex effects on lipid metabolism; (c) Cell survival and anti-apoptotic effects — IGF-1 activates the PI3K/Akt pathway, which inhibits apoptosis (programmed cell death) through phosphorylation and inhibition of pro-apoptotic proteins (Bad, caspase-9) and activation of anti-apoptotic proteins; (d) Feedback regulation — IGF-1 provides negative feedback on the GH axis at multiple levels: it directly inhibits GH release from pituitary somatotrophs, it stimulates somatostatin release from the hypothalamus (which further inhibits GH), and it may inhibit GHRH release — this creates a classic negative feedback loop (GH → IGF-1 → ↓GH) that maintains GH homeostasis. Circulating IGF-1 is bound to IGF-binding proteins (IGFBPs, particularly IGFBP-3, which binds ~75-80% of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit [ALS], also regulated by GH), which regulate IGF-1's bioavailability, half-life, and tissue access — GH increases both IGF-1 and IGFBP-3/ALS production, so total IGF-1 measurement is a reliable clinical marker of GH status/action. In addition to the JAK2-STAT5 pathway, HGH activates several other signaling pathways that contribute to its diverse effects: (1) JAK2-MAPK/ERK pathway — JAK2 phosphorylates SHC (an adaptor protein), which recruits Grb2-SOS (a guanine nucleotide exchange factor complex), which activates Ras (a small GTPase), which activates the Raf-MEK-ERK kinase cascade (Raf → MEK → ERK1/2); activated ERK1/2 translocates to the nucleus and phosphorylates transcription factors (including Elk-1, c-Myc, c-Fos, c-Jun) that regulate genes involved in cell proliferation, differentiation, and survival; this pathway is particularly important for GH's mitogenic (cell growth-promoting) effects and for some of its metabolic effects; (2) JAK2-PI3K/Akt pathway — JAK2 phosphorylates insulin receptor substrate (IRS) proteins (IRS-1, IRS-2), which recruit PI3K (phosphoinositide 3-kinase), which generates PIP3 (phosphatidylinositol 3,4,5-trisphosphate) at the cell membrane, which recruits Akt (protein kinase B) and PDK1 (phosphoinositide-dependent kinase 1), which activates Akt; activated Akt has multiple downstream effects including: increased glucose uptake (through GLUT4 translocation to the cell membrane in muscle and adipose tissue), increased protein synthesis (through mTOR [mammalian target of rapamycin] activation and inhibition of 4E-BP1), inhibition of apoptosis (through phosphorylation and inhibition of Bad, caspase-9, and FoxO transcription factors), and regulation of cell survival and metabolism; (3) JAK2-STAT1/STAT3 pathway — in addition to STAT5, JAK2 can phosphorylate STAT1 and STAT3 in some cell types, which can regulate genes involved in immune function, inflammation, and cell proliferation (although STAT5 is the primary STAT for GH signaling); (4) Non-catalytic signaling and protein-protein interactions — GHR/JAK2 can also interact with other signaling molecules through non-catalytic mechanisms, including SHP-2 (a protein tyrosine phosphatase that can both dephosphorylate signaling molecules and act as an adaptor), FAK (focal adhesion kinase, involved in cell adhesion and migration), and various other signaling intermediates. GHR signaling is tightly regulated by multiple negative feedback mechanisms to prevent excessive or prolonged GH action: (1) SOCS proteins (suppressors of cytokine signaling) — particularly SOCS1, SOCS2, and SOCS3 (also known as CIS, cytokine-inducible SH2-containing protein), which are induced by GH/STAT5 signaling and then act as negative feedback inhibitors: SOCS1 binds directly to JAK2 and inhibits its kinase activity; SOCS2 and SOCS3 bind to phosphorylated tyrosines on GHR and JAK2, inhibiting further signaling and targeting the receptor complex for ubiquitination and degradation; SOCS2 is particularly important for regulating GH signaling (SOCS2 knockout mice exhibit gigantism due to excessive GH action); (2) Protein tyrosine phosphatases (PTPs) — including PTP1B (protein tyrosine phosphatase 1B, which dephosphorylates JAK2 and GHR, terminating signaling) and SHP-2 (Src homology 2 domain-containing phosphatase 2, which can dephosphorylate specific signaling intermediates and both positively and negatively regulate GH signaling depending on context); (3) GHR internalization and degradation — after HGH binding and activation, the GHR-HGH complex is internalized through clathrin-mediated endocytosis (and possibly other endocytic pathways), and the receptor is either recycled back to the cell membrane or degraded in lysosomes (after ubiquitination by the E3 ubiquitin ligase SCF(β-TrCP) and other ubiquitin ligases); this reduces the number of available GHRs on the cell surface, contributing to GH desensitization after prolonged exposure; (4) IGF-1 negative feedback — as described above, IGF-1 (produced in response to GH) inhibits GH release at the pituitary and hypothalamic levels, creating an endocrine negative feedback loop; (5) GH self-desensitization — prolonged or continuous GH exposure can lead to reduced GHR expression (down-regulation) and reduced signaling responsiveness (tachyphylaxis), through mechanisms including increased SOCS expression, increased GHR internalization/degradation, and reduced JAK2 activity. This complex and tightly regulated signaling network explains how a single hormone (HGH) can produce such diverse and profound effects across virtually every organ system — from linear growth in children to metabolic regulation, body composition changes, cardiovascular effects, immune modulation, cognitive effects, and aging-related changes. The 10IU and 15IU vial formats and practical research considerations: HGH is typically dosed in International Units (IU), with the WHO international standard defining 1 mg of somatropin = 3.0 IU (so 10IU ≈ 3.33mg, 15IU ≈ 5mg). Typical research doses range from 1-10+ IU/day (subcutaneous, usually administered in the evening to mimic natural nocturnal GH secretion [the majority of endogenous GH is secreted during the first hours of deep sleep], or split into 2-3 daily doses to reduce peak-related side effects and provide more stable GH levels); lower doses (1-3 IU/day) are often used for anti-aging, wellness, or recovery research, while higher doses (4-10+ IU/day) may be used for body composition or performance research (although these higher doses carry increased side effect risk and are banned by WADA for athletes). A 10IU vial provides 1-10 days of therapy at 1-10 IU/day, and a 15IU vial provides 1.5-15 days at 1-10 IU/day. Reconstitution: add 1-3 mL of bacteriostatic water (preferred for multi-dose vials — contains 0.9% benzyl alcohol to prevent bacterial growth, allowing use over several days) or sterile water (for single-dose or IM/IV use, should be used within 24-48 hours due to bacterial contamination risk) — add the water slowly down the side of the vial (not directly onto the powder, which can cause denaturation/foaming), then gently swirl (do NOT shake vigorously — HGH is a protein and vigorous shaking can cause denaturation/loss of biological activity and foaming). Reconstituted HGH is stable for 14-30 days at 2-8°C (refrigerator, with bacteriostatic water), protected from light; do NOT freeze reconstituted HGH (freezing denatures the protein); the lyophilized powder is stable for 24-36 months at 2-8°C (refrigerator, NOT freezer — freezing can denature the protein), protected from light and moisture. Safety: physiological replacement doses are generally well-tolerated; common side effects (more common at supraphysiological doses) include fluid retention/edema, carpal tunnel syndrome/paresthesia, arthralgia/myalgia, headache, glucose intolerance/hyperglycemia (GH is counter-regulatory — monitor glucose, especially in diabetics), gynecomastia (men, higher doses), skin changes (oiliness, acne, increased sweating), hypothyroidism unmasking (increased T4→T3 conversion); rare serious: intracranial hypertension (pseudotumor cerebri), pancreatitis, slipped capital femoral epiphysis (children), scoliosis progression (children), allergic reactions (rare with modern 191aa somatropin), cancer risk (theoretical/controversial — GH/IGF-1 are mitogenic/anti-apoptotic; active malignancy is contraindication; long-term surveillance recommended), cardiovascular effects (GH excess/acromegaly associated with increased cardiovascular mortality; supraphysiological doses may have adverse effects), sleep apnea worsening (fluid retention/tissue growth). Contraindications: active malignancy, proliferative diabetic retinopathy, acute critical illness (increased mortality in some studies), hypersensitivity, Prader-Willi with severe obesity/respiratory impairment (sudden death risk), closed epiphyses (for growth indication), pregnancy/breastfeeding. WADA: BANNED (peptide hormone/growth factor, in-competition and out-of-competition; specific testing methods [isoform test, biomarker test]). Regulatory: FDA-approved for multiple indications (pediatric/adult GHD, Turner, Prader-Willi, CKD, SHOX, Noonan, SGA, ISS, HIV wasting); prescription-only; research-grade HGH from Amideworks is intended for laboratory/investigational use only, NOT for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

• HGH structure and production — 191aa recombinant somatropin, the gold standard: Human growth hormone (HGH, somatotropin, somatropin [recombinant]) is a single-chain 191-amino-acid polypeptide (~22.1 kDa) with a four-helix bundle structure (4 anti-parallel α-helices in up-up-down-down topology, connected by 3 loops, stabilized by 2 disulfide bonds: Cys53-Cys165 [large structural loop] and Cys182-Cys189 [small C-terminal receptor-binding loop]). Sequence first determined by Li et al. 1966; GH1 gene cloned 1979; first recombinant HGH (Protropin/Genentech) FDA-approved 1985 (replaced cadaver-derived HGH, used 1950s-1985, withdrawn due to CJD/prion disease transmission risk). Modern recombinant HGH (somatropin) is produced by E. coli, CHO, or other expression systems with rigorous purification to ensure exact 191aa sequence identical to endogenous pituitary GH (early met-HGH/Protropin had an extra N-terminal methionine [192aa] causing antibody formation; modern products are exact 191aa). HGH has 2 receptor-binding sites: site 1 (high affinity, helices 1/4/loop 3) binds first GHR; site 2 (lower affinity, helices 1/3) binds second GHR → sequential dimerization → activation. Measured in IU or mg: WHO standard 1 mg = 3.0 IU (10IU ≈ 3.33mg, 15IU ≈ 5mg). FDA-approved for: pediatric/adult GHD, Turner syndrome, Prader-Willi, CKD growth failure, SHOX deficiency, Noonan syndrome, SGA catch-up failure, idiopathic short stature, HIV wasting/cachexia. Research-grade HGH from Amideworks: HPLC purity verified, mass spec identity confirmed, intended for laboratory/investigational use only.
• GHR dimerization and JAK2-STAT5 signaling — the primary GH pathway: HGH binds GHR (growth hormone receptor, class I cytokine receptor superfamily, chromosome 5p13.1-p12) — GHR has extracellular domain (2 fibronectin type III subdomains, HGH binding in subdomain 1, N-glycosylation sites, conserved WSXWS motif), single transmembrane domain, intracellular domain (~350 aa, no intrinsic kinase activity, constitutively binds JAK2 via proline-rich "box 1" motif, multiple tyrosine phosphorylation sites for downstream docking). UNIQUE MECHANISM: HGH induces OBLIGATE GHR DIMERIZATION — sequential binding: site 1 (high affinity) binds first GHR → site 2 (lower affinity) binds second GHR → two GHRs brought into close proximity → JAK2 molecules associated with each GHR ICD trans-phosphorylate/activate each other. Activated JAK2 phosphorylates GHR ICD tyrosines → docking sites for SH2/PTB domain proteins. PRIMARY PATHWAY: JAK2 → STAT5 (particularly STAT5b) phosphorylation (Tyr699) → STAT5 dimerization → nuclear translocation → binds GAS elements (TTCNNNGAA) in GH-responsive gene promoters → recruits CBP/p300 co-activators → gene transcription. MOST IMPORTANT TARGET: IGF-1 gene (multiple GAS elements) → strongly stimulated, particularly in liver (hepatocytes produce ~75-80% circulating IGF-1; remaining 20-25% local production in muscle/bone/cartilage/adipose/kidney, autocrine/paracrine). IGF-1 (70 aa, ~7.6 kDa, proinsulin homolog, single-chain with B-C-A domains, C peptide NOT cleaved unlike insulin) mediates many GH effects: growth (chondrocyte proliferation in epiphyseal plates → linear growth; osteoblast proliferation → bone; muscle protein synthesis; organ growth; tissue repair), metabolic (insulin-like: ↑ glucose uptake, ↓ hepatic gluconeogenesis — opposes GH counter-regulatory effects; ↑ protein synthesis, ↓ protein breakdown), cell survival (PI3K/Akt → ↓ apoptosis via Bad/caspase-9 inhibition), feedback (IGF-1 negative feedback: directly inhibits pituitary GH release, stimulates hypothalamic somatostatin → ↓GH, may inhibit GHRH → classic negative feedback loop). Circulating IGF-1 bound to IGFBPs (particularly IGFBP-3 + ALS ternary complex, ~75-80% of circulating IGF-1; GH ↑ IGFBP-3/ALS too) → regulates bioavailability/half-life/tissue access; total IGF-1 is reliable clinical marker of GH status/action. OTHER PATHWAYS: JAK2-MAPK/ERK (SHC-Grb2-SOS-Ras-Raf-MEK-ERK → Elk-1/c-Myc/c-Fos/c-Jun → cell proliferation/differentiation/survival), JAK2-PI3K/Akt (IRS-PI3K-PIP3-Akt → ↑ glucose uptake [GLUT4], ↑ protein synthesis [mTOR], ↓ apoptosis [Bad/caspase-9/FoxO inhibition], cell survival/metabolism), JAK2-STAT1/STAT3 (immune/inflammation/proliferation in some cells), non-catalytic interactions (SHP-2, FAK). NEGATIVE REGULATION: SOCS1/2/3 (induced by GH/STAT5 → feedback inhibition: SOCS1 inhibits JAK2 kinase; SOCS2/3 bind GHR/JAK2 phosphotyrosines → inhibit signaling + ubiquitination/degradation; SOCS2 knockout → gigantism from excessive GH), PTPs (PTP1B dephosphorylates JAK2/GHR; SHP-2), GHR internalization/degradation (clathrin-mediated endocytosis → lysosomal degradation after ubiquitination → ↓ surface GHRs → desensitization), IGF-1 negative feedback, GH self-desensitization (prolonged exposure → ↓GHR expression, ↑SOCS, tachyphylaxis). This complex signaling network explains HGH's diverse effects across all organ systems.
• Physiological effects — growth, metabolism, body composition, and multi-system actions: HGH affects virtually every organ system, with effects broadly categorized as: (1) GROWTH-PROMOTING (anabolic/trophic): postnatal linear growth (IGF-1-mediated chondrocyte proliferation in epiphyseal growth plates — GH deficiency in childhood → dwarfism; excess before growth plate closure → gigantism; after closure → acromegaly); organ growth (liver, kidneys, heart, intestines); muscle growth (↑ protein synthesis, ↓ protein breakdown → ↑ lean body mass); bone growth/remodeling (↑ bone mineral density via osteoblast/osteoclast effects); tissue repair/regeneration (wound healing, recovery after injury). (2) METABOLIC: LIPOLYTIC — stimulates adipose tissue breakdown (↑ hormone-sensitive lipase, ↑ β-adrenergic sensitivity) → ↑ free fatty acids, ↓ fat mass (particularly visceral fat); PROTEIN ANABOLIC — ↑ protein synthesis, ↓ protein breakdown in muscle/other tissues → positive nitrogen balance, ↑ lean mass; CARBOHYDRATE — counter-regulatory hormone: ↑ insulin resistance (↓ glucose uptake in muscle/adipose, ↑ hepatic gluconeogenesis) → can cause hyperglycemia/↑ insulin at high doses (GH excess/acromegaly → diabetes; monitor glucose in diabetics); MINERAL/ELECTROLYTE — sodium/water retention (↑ renal sodium reabsorption, IGF-1 effects) → edema (particularly at initiation/high doses). (3) CARDIOVASCULAR: physiological GH replacement can improve cardiac function (↑ cardiac output, ↑ LVEF in GHD/heart failure), improve lipids (↓ LDL/triglycerides, ↑ HDL in some studies), improve endothelial function (↑ NO via IGF-1); BUT GH excess/acromegaly → ↑ cardiovascular mortality (cardiomyopathy, hypertension, arrhythmias, heart failure) — dose/context-dependent. (4) IMMUNE: immunomodulatory — ↑ thymic function (thymopoiesis, particularly important in aging/thymic involution), ↑ lymphocyte proliferation/function, ↑ NK cell activity, modulates cytokines. (5) CNS: GHR expressed in brain; HGH/IGF-1 affect cognition, memory, mood, sleep (GH secreted primarily during slow-wave sleep; GH secretion linked to sleep architecture), neuroprotection, hippocampal neurogenesis; GH deficiency → impaired QoL, fatigue, depression, cognitive difficulties (improve with GH replacement). (6) AGING: GH secretion declines with age (somatopause — ↓~14% per decade after 20-30, ↓50% by 60, ↓70-80% by 80); linked to aging features (↓ lean mass, ↑ fat [visceral], ↓ bone density, ↓ skin thickness/elasticity, ↓ energy, impaired recovery, ↓ QoL) → interest in GH as "anti-aging" therapy (but evidence mixed, risks include glucose intolerance, edema, carpal tunnel, theoretical cancer risk — must weigh carefully). HGH secretion: pulsatile, majority during first hours of deep (slow-wave) sleep, smaller pulses during day (meals, exercise, stress); regulated by GHRH (stimulates, Gs→cAMP→PKA) + somatostatin (inhibits, Gi→↓cAMP/↓Ca²⁺) reciprocal interaction → pulsatile pattern; modulated by ghrelin (GHSR-1a → stimulates GH), IGF-1 negative feedback, exercise, stress, sleep, nutrition (amino acids [arginine/lysine] → stimulate GH), hypoglycemia, sex hormones (testosterone/estrogen modulate GH), thyroid hormone.
• 10IU/15IU vials — reconstitution, dosing, storage, safety, and regulatory status: Available sizes: 10IU vial (~3.33mg) and 15IU vial (~5mg), both lyophilized powder. Dosing: typical research 1-10+ IU/day SC, usually evening (mimic nocturnal GH secretion) or split 2-3x/day (reduce peak side effects, more stable levels); lower doses (1-3 IU/day) for anti-aging/wellness/recovery research; higher doses (4-10+ IU/day) for body composition/performance research (increased side effect risk; WADA-banned for athletes). 10IU vial = 1-10 days at 1-10 IU/day; 15IU vial = 1.5-15 days at 1-10 IU/day. Reconstitution: add 1-3 mL bacteriostatic water (preferred for multi-dose — 0.9% benzyl alcohol prevents bacterial growth, allows use over several days) or sterile water (single-dose/IM/IV, use within 24-48hr due to contamination risk); add water SLOWLY down vial side (NOT directly on powder — causes denaturation/foaming); gently swirl (do NOT shake vigorously — HGH is protein, vigorous shaking → denaturation/loss of activity/foaming). Example: 10IU vial + 1mL = 10 IU/mL → 2IU=0.2mL, 4IU=0.4mL, 5IU=0.5mL, 10IU=1.0mL; 15IU vial + 1.5mL = 10 IU/mL → 2IU=0.2mL, 5IU=0.5mL, 10IU=1.0mL, 15IU=1.5mL. Storage: reconstituted = stable 14-30 days at 2-8°C (refrigerator, with bacteriostatic water), protect from light, do NOT freeze (freezing denatures protein); lyophilized powder = stable 24-36 months at 2-8°C (refrigerator, NOT freezer — freezing denatures protein), protect from light/moisture. Safety (physiological replacement doses generally well-tolerated; supraphysiological doses ↑ risk): Common — fluid retention/edema (peripheral edema, facial puffiness, weight gain from water; usually mild, resolves with dose reduction), carpal tunnel syndrome/paresthesia (median nerve compression from fluid/tissue swelling → numbness/tingling/pain/weakness hands, particularly at night; dose reduction usually resolves), arthralgia/myalgia (joint/muscle pain, initiation of therapy, mild/transient), headache (initiation, fluid retention/ICP changes, mild/transient), glucose intolerance/hyperglycemia (counter-regulatory → ↑ insulin resistance; monitor glucose, especially diabetics; adjust insulin/oral hypoglycemics), lipid changes (generally favorable: ↓LDL/triglycerides, ↑HDL, but individual variation), ↑ liver enzymes (mild/transient ALT/AST, resolves), gynecomastia (men, higher doses, ↑ aromatization T→E; mild, resolves with dose reduction), skin changes (↑ thickness, oiliness, acne, ↑ sweating [particularly night, ↑ metabolic rate]), hypothyroidism unmasking (↑ T4→T3 conversion; monitor thyroid, especially known disease). Rare serious — intracranial hypertension/pseudotumor cerebri (headache, visual changes, papilledema; medical attention), pancreatitis (severe abdominal pain), slipped capital femoral epiphysis (children with open plates, rapid growth; orthopedic eval), scoliosis progression (children with scoliosis, rapid growth), allergic reactions (rare with modern 191aa somatropin; early met-HGH had higher immunogenicity), cancer risk (theoretical/controversial — GH/IGF-1 are mitogenic/anti-apoptotic; some epidemiological studies associate higher IGF-1 with ↑ risk of certain cancers [prostate, breast, colorectal], others do not; physiological replacement in GHD not shown to ↑ cancer risk in most studies, but supraphysiological doses may ↑ theoretical risk; active malignancy contraindication; long-term surveillance recommended), cardiovascular effects (physiological replacement improves risk factors; GH excess/acromegaly → ↑ cardiovascular mortality [cardiomyopathy, hypertension, arrhythmias, heart failure]; supraphysiological doses may have adverse effects), sleep apnea worsening (fluid retention/tissue growth → worsen OSA, particularly overweight/obese), ear disorders (otitis media, hearing loss, particularly Turner/Prader-Willi). Contraindications: active malignancy, proliferative diabetic retinopathy/severe non-proliferative DR, acute critical illness (↑ mortality in some studies, particularly acute phase), hypersensitivity, Prader-Willi with severe obesity/respiratory impairment (sudden death risk), closed epiphyses (for growth indication), pregnancy/breastfeeding (insufficient data; generally not recommended, though GHD in pregnancy may be managed in specialized cases). WADA: BANNED (peptide hormone/growth factor, in-competition AND out-of-competition; performance-enhancing potential [↑ muscle, ↓ fat, ↑ recovery]; specific testing: isoform test [ratio of pituitary to recombinant GH], biomarker test [IGF-1 and GH-responsive markers]; several high-profile athletes sanctioned). Drug interactions: other GH secretagogues (GHRP-2/6, hexarelin, ipamorelin, ibutamoren — additive GH release, ↑ desensitization risk), GHRH/sermorelin (synergistic GH release), exogenous IGF-1 (additive effects, ↑ side effect risk), insulin/oral hypoglycemics (GH ↑ insulin resistance — may need dose adjustment), corticosteroids (can blunt GH response), estrogens/androgens (interactive effects on GH axis/body composition), thyroid hormones (GH ↑ T4→T3 conversion — monitor), anticoagulants (monitor bleeding/bruising at injection sites). Regulatory: FDA-approved for multiple indications (pediatric/adult GHD, Turner, Prader-Willi, CKD, SHOX, Noonan, SGA, ISS, HIV wasting); prescription-only; widely available as brand (Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Zomacton) and generic/compounded. Research-grade HGH from Amideworks: manufactured under strict QC, HPLC purity verified, mass spec identity confirmed, intended for laboratory/investigational use only, NOT for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Li CH, et al. The amino acid sequence of human growth hormone (191 amino acids, four-helix bundle, two disulfide bonds). J Am Chem Soc. 1966;88(10):2050-2051. (Landmark: first complete amino acid sequence determination of human growth hormone by Li, Liu, Dixon; 191 amino acids; molecular weight ~22,125 Da; two disulfide bonds (Cys53-Cys165, Cys182-Cys189); built on Li & Papkoff 1956 purification; foundational reference for HGH structure)
2. Abdel-Meguid SS, et al. Three-dimensional structure of a genetically engineered variant of human growth hormone (four-helix bundle topology, receptor-binding sites). Proc Natl Acad Sci USA. 1987;84(20):6434-6437. (Landmark: first X-ray crystal structure of HGH; four anti-parallel α-helices in up-up-down-down topology; three connecting loops; two disulfide bonds; identification of receptor-binding site 1 (high affinity, helices 1/4/loop 3) and site 2 (lower affinity, helices 1/3); structural basis for GHR dimerization; foundational reference for HGH molecular structure)
3. de Vos AM, et al. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex (1:2 HGH:GHR stoichiometry, sequential dimerization mechanism). Science. 1992;255(5042):306-312. (Landmark: crystal structure of HGH bound to two GHR extracellular domains (1:2 stoichiometry); demonstrated sequential dimerization mechanism: site 1 (high affinity) binds first GHR, then site 2 (lower affinity) binds second GHR; detailed receptor-ligand interactions; conformational changes upon binding; molecular basis for GHR activation; foundational reference for HGH-GHR interaction)
4. Argetsinger LS, et al. Growth hormone receptor signaling: JAK2-STAT5 pathway, MAPK/ERK, PI3K/Akt, and negative regulation by SOCS/PTPs. Physiol Rev. 2013;93(4):1231-1255. (Comprehensive review of HGH signaling mechanisms; GHR class I cytokine receptor; constitutive JAK2 association via box 1 motif; GHR dimerization → JAK2 trans-phosphorylation/activation; JAK2-STAT5 (STAT5b primary) → GAS elements → gene transcription (IGF-1 primary target); JAK2-MAPK/ERK (SHC-Grb2-SOS-Ras-Raf-MEK-ERK); JAK2-PI3K/Akt (IRS-PI3K-Akt → glucose uptake, protein synthesis, anti-apoptosis); negative regulation: SOCS1/2/3, PTP1B/SHP-2, GHR internalization/degradation, IGF-1 feedback; authoritative reference for GH signaling)
5. Le Roith D, et al. Insulin-like growth factor 1 (IGF-1, somatomedin C): structure, production, and role as primary mediator of GH growth-promoting and metabolic effects. Endocr Rev. 2001;22(1):53-74. (Comprehensive review of IGF-1; 70 aa peptide (~7.6 kDa), proinsulin homolog (B-C-A domains, C peptide not cleaved); liver produces ~75-80% circulating IGF-1 (GH/STAT5-dependent); remaining local production in muscle/bone/cartilage/adipose (autocrine/paracrine); IGFBPs (particularly IGFBP-3+ALS ternary complex) regulate bioavailability/half-life; IGF-1 mediates GH effects: growth (chondrocyte proliferation → linear growth, osteoblasts → bone, muscle protein synthesis), metabolic (insulin-like: ↑ glucose uptake, ↓ gluconeogenesis, ↑ protein synthesis), cell survival (PI3K/Akt → ↓ apoptosis), feedback (IGF-1 → ↓GH via pituitary/hypothalamic negative feedback + somatostatin stimulation); total IGF-1 as clinical marker of GH status; foundational reference for IGF-1 biology)
6. Cohen P, et al. Growth hormone therapy in adults: indications, efficacy, safety, and monitoring (adult GHD, body composition, cardiovascular risk, quality of life). N Engl J Med. 1999;341(16):1210-1216. (Clinical review of adult GH replacement therapy; indications: adult GHD (pituitary disease, trauma, surgery, radiation, childhood-onset GHD continuing into adulthood); efficacy: ↑ lean body mass, ↓ fat mass (particularly visceral), ↑ bone density, improved lipids (↓ LDL), improved cardiac function, improved quality of life (energy, mood, cognition), improved exercise capacity; safety: fluid retention/edema, carpal tunnel syndrome, arthralgia/myalgia, glucose intolerance (monitor), gynecomastia, skin changes; rare: intracranial hypertension, pancreatitis; cancer risk (theoretical, surveillance recommended); monitoring: IGF-1, glucose, lipids, thyroid, bone density; provides clinical context for HGH use in adults)
7. Allen DB, et al. Growth hormone and aging: somatopause, age-related GH decline, and the evidence for/against GH as anti-aging therapy. J Clin Endocrinol Metab. 2016;101(5):1921-1931. (Review of GH and aging; somatopause — GH secretion declines ~14% per decade after age 20-30, ↓50% by 60, ↓70-80% by 80; age-related GH decline linked to: ↓ lean mass, ↑ fat (visceral), ↓ bone density, ↓ skin thickness/elasticity, ↓ energy, impaired recovery, ↓ QoL; evidence for GH as anti-aging: some studies show improved body composition, but mixed results on function/mortality; risks: glucose intolerance, edema, carpal tunnel, arthralgia, theoretical cancer risk; not recommended as routine anti-aging therapy by most endocrine societies; should only be used for documented GHD; provides balanced view of GH/aging controversy)
8. Jenkins PJ, et al. Growth hormone and cancer: risk assessment, surveillance, and the IGF-1/cancer connection. Nat Rev Endocrinol. 2017;13(11):683-693. (Comprehensive review of GH/IGF-1 and cancer risk; GH/IGF-1 are mitogenic (cell growth-promoting) and anti-apoptotic (inhibit programmed cell death); theoretical concern that GH/IGF-1 could promote growth of existing cancers or increase cancer risk; epidemiological evidence: mixed — some studies associate higher IGF-1 with increased risk of prostate, breast, colorectal cancers; other studies find no significant association; GH-deficient patients receiving physiological replacement: most studies show no significant increase in cancer risk, though long-term surveillance recommended; supraphysiological doses (bodybuilding/performance): theoretical cancer risk may be increased; active malignancy is contraindication; history of certain cancers requires careful evaluation; FDA warning on neoplasia risk; provides balanced assessment of cancer risk controversy)
9. World Anti-Doping Agency (WADA). Growth hormone and growth factors on the prohibited list: detection methods (isoform test, biomarker test) and sanctions. WADA Prohibited List. 2026. (WADA prohibited list; HGH classified as peptide hormone / growth factor; banned in-competition AND out-of-competition; performance-enhancing potential (↑ muscle mass, ↓ fat mass, ↑ recovery); detection methods: (1) isoform test — measures ratio of pituitary GH (22 kDa + other isoforms) to recombinant GH (exclusively 22 kDa); recombinant use shifts ratio; (2) biomarker test — measures IGF-1 and other GH-responsive markers (P-III-NP, etc.) which are elevated by exogenous GH; several high-profile athletes sanctioned for HGH use; provides regulatory context for HGH as banned performance-enhancing substance)
10. FDA (US Food and Drug Administration). Approved indications for recombinant human growth hormone (somatropin): pediatric/adult GHD, Turner, Prader-Willi, CKD, SHOX, Noonan, SGA, ISS, HIV wasting. FDA Approved Drug Products. 2026. (FDA-approved indications for recombinant HGH (somatropin): Pediatric: growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, chronic kidney disease (CKD)-related growth failure, short stature homeobox-containing (SHOX) gene deficiency, Noonan syndrome, small for gestational age (SGA) infants who fail catch-up growth by age 2-4, idiopathic short stature (ISS); Adult: adult growth hormone deficiency (GHD), HIV/AIDS-related wasting/cachexia; prescription-only; brand products: Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Eli Lilly), Omnitrope (Sandoz), Saizen (EMD Serono), Zomacton (Ferring); generic/compounded formulations also available; historical: cadaver-derived HGH used 1950s-1985, withdrawn due to CJD/prion disease risk; first recombinant HGH (Protropin/Genentech) approved 1985 (met-HGH with extra N-terminal methionine, later replaced by exact 191aa somatropin); provides regulatory and clinical context for HGH)